Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Setmelanotide in Patients With Acquired Hypothalamic Obesity

NCT06760546 is registered in ClinicalTrials.gov with Rhythm Pharmaceuticals, Inc. as lead sponsor.

NCT NCT06760546
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06760546 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Setmelanotide in Patients With Acquired Hypothalamic Obesity
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
September 23, 2025
Completion date
March 13, 2028
Enrollment
39 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

childhood-onset combined pituitary hormone deficiency, hypothalamic obesity, multiple pituitary hormone deficiency genetic form, optic nerve hypoplasia, pituitary stalk interruption syndrome, septo-optic dysplasia